CGEN News and Press, Compugen Ltd.

2026-03-02 14:35:28 ET The last time I spoke about Compugen ( CGEN ), it was with respect to a Seeking Alpha article entitled " Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients ." With respect to this article, I went over the fact that th...

2026-03-02 11:17:54 ET Compugen Ltd. (CGEN) Q4 2025 Earnings Call March 2, 2026 8:30 AM EST Company Participants Eran Ophir - CEO & Director David Silberman - Chief Financial Officer Michelle Mahler - Chief Medical Officer ... Read the full article on...

2026-03-02 09:56:20 ET Image source: The Motley Fool. Monday, March 2, 2026 at 8:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-03-02 07:03:39 ET More on Compugen Compugen rises on royalty deal with AstraZeneca Seeking Alpha’s Quant Rating on Compugen Historical earnings data for Compugen Financial information for Compugen Read the full article on Seeking Alpha ...

Compugen Reports Fourth Quarter and Full Year 2025 Results PR Newswire Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029 Enhanced leadership team w...

Astrana Health Inc. (ASTH) is expected to report $0.15 for Q4 2025 Sealed Air Corporation (SEE) is expected to report $0.72 for Q4 2025 Surgery Partners Inc. (SGRY) is expected to report $0.27 for Q4 2025 Kuehne + Nagel International AG ADR (KHNGY) is expected to report $0.4 for Q4 20...

2026-02-27 14:15:17 ET More on Compugen Compugen rises on royalty deal with AstraZeneca Seeking Alpha’s Quant Rating on Compugen Historical earnings data for Compugen Financial information for Compugen Read the full article on Seeking Alpha ...

Compugen to Participate in Upcoming Investor Conferences PR Newswire HOLON, Israel , Feb. 19, 2026 /PRNewswire/ -- Compugen Ltd.  (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML,...

Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026 PR Newswire HOLON, Israel , Feb. 17, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target d...

Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors PR Newswire HOLON, Israel , Feb. 12, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target ...